Alyeska Investment Group L.P. Makes New $108.25 Million Investment in Agilent Technologies, Inc. $A

Key Points

• Alyeska Investment Group initiated a $108.25 million position in Agilent Technologies, purchasing 814,971 shares, or approximately 0.29% of the company.
• Agilent’s fiscal third-quarter results exceeded expectations, with EPS of $1.62 and revenue of $1.88 billion; revenue rose 8.1% year over year. Management also raised full-year guidance, citing stronger product momentum, improving China demand and expanding margins.
• Analysts remain broadly positive, with a “Moderate Buy” consensus and an average price target of $170.33, but Agilent’s valuation near 30 times earnings and a PEG ratio above 2.6 leave the stock vulnerable to weaker demand or disappointing guidance.

Alyeska Investment Group L.P. purchased a new stake in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 814,971 shares of the medical research company's stock, valued at approximately $108,253,000. Alyeska Investment Group L.P. owned approximately 0.29% of Agilent Technologies as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of A. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in shares of Agilent Technologies by 4.3% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 599,581 shares of the medical research company's stock valued at $82,712,000 after acquiring an additional 24,687 shares during the period. Bank of Nova Scotia acquired a new position in Agilent Technologies in the 2nd quarter worth approximately $58,539,000. Dudley & Shanley Inc. grew its position in Agilent Technologies by 25.9% during the 2nd quarter. Dudley & Shanley Inc. now owns 69,500 shares of the medical research company's stock worth $9,232,000 after purchasing an additional 14,300 shares in the last quarter. BIP Wealth LLC purchased a new position in Agilent Technologies during the 2nd quarter worth approximately $834,000. Finally, Crossmark Global Holdings Inc. raised its stake in Agilent Technologies by 39.6% during the 4th quarter. Crossmark Global Holdings Inc. now owns 33,918 shares of the medical research company's stock valued at $4,615,000 after purchasing an additional 9,615 shares during the period.

Agilent Technologies News Roundup

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Agilent reported fiscal Q3 earnings of $1.62 per share, above the $1.48-$1.49 analyst consensus, while revenue of approximately $1.88 billion also exceeded expectations. EPS increased from $1.37 a year earlier, supporting the view that profitability is improving. Agilent Technologies Q3 Earnings and Revenues Top Estimates
• Positive Sentiment: Management raised its full-year guidance following the strong quarter. Commentary highlighted product momentum, a recovery in China, improving demand and expanding margins, all of which could support additional earnings growth. Agilent Technologies Lifts Outlook After Strong Quarter
• Positive Sentiment: Several major firms raised their price targets and maintained bullish ratings after the results. Targets now range from $175 to $190, with upgrades from JPMorgan, Citi, Barclays, Goldman Sachs, Bank of America, Stifel, TD Cowen, Bernstein and RBC. Analysts Raise Agilent Technologies Price Targets
• Neutral Sentiment: Despite the improved outlook, valuation remains relatively demanding: Agilent trades at roughly 30 times earnings, with a PEG ratio above 2.7. This leaves the stock sensitive to any slowdown in demand or disappointment in future guidance.

Agilent Technologies Trading Down 2.0%

NYSE:A opened at $154.47 on Friday. The stock's 50 day moving average price is $140.30 and its 200 day moving average price is $127.04. Agilent Technologies, Inc. has a 52 week low of $108.35 and a 52 week high of $163.75. The company has a market capitalization of $43.63 billion, a P/E ratio of 30.41, a P/E/G ratio of 2.65 and a beta of 1.25. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.62 and a current ratio of 2.05.

Agilent Technologies (NYSE:A - Get Free Report) last posted its earnings results on Wednesday, August 26th. The medical research company reported $1.62 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.49 by $0.13. The firm had revenue of $1.88 billion during the quarter, compared to analysts' expectations of $1.84 billion. Agilent Technologies had a net margin of 19.53% and a return on equity of 24.45%. The company's revenue was up 8.1% compared to the same quarter last year. During the same period in the previous year, the company earned $1.37 earnings per share. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. On average, research analysts forecast that Agilent Technologies, Inc. will post 6.2 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A has been the subject of a number of research analyst reports. Wolfe Research restated a "hold" rating on shares of Agilent Technologies in a report on Tuesday, June 2nd. The Goldman Sachs Group lifted their price target on Agilent Technologies from $155.00 to $175.00 and gave the company a "buy" rating in a report on Thursday. Robert W. Baird increased their price objective on Agilent Technologies from $155.00 to $156.00 and gave the stock an "outperform" rating in a research note on Tuesday, May 26th. Stifel Nicolaus raised their price objective on Agilent Technologies from $170.00 to $180.00 and gave the stock a "buy" rating in a research report on Thursday. Finally, HSBC decreased their price objective on Agilent Technologies from $180.00 to $165.00 and set a "buy" rating for the company in a research report on Wednesday, June 3rd. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, Agilent Technologies presently has an average rating of "Moderate Buy" and an average price target of $170.33.

Agilent Technologies Profile

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company's product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source